Wockhardt to market SAMMY, a tablet for osteoarthritis

Ahmedabad, Oct 18 (UNI) Pharmaceutical major, Wockhardt has signed an in-licensing agreement with Italy-based Gnosis SpA to market SAMe (S-adenosyl methionine), a process patented product for osteoarthritis.

SAMe will be marketed under the brand name ''SAMMY'' which will further strengthen our osteoarthritis portfolio, company sources said.

Osteoarthritis (OA) is a condition in which low-grade inflammation results in pain in the joints, caused by wear and tear of the cartilage.

It is estimated that 80 per cent of the Indian population will have radiographic evidence of OA by the age of 65, which is alarming considering the increase of ageing population in India.

SAMMY in addition to pain relief plays an important role in cartilage formation and repair.

Gnosis SpA and Wockhardt are a global Pharmaceutical and biotechnology companies specialising in research and development of innovative processes in the field of biotechnology.

UNI